Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Survival improves in clinical trial for severe birth defect, with or without fetal surgery

14.11.2003


Endoscopic fetal treatment increases survival to 73 percent for a severe defect that hampers lung growth -- comparison group in a randomized trial increases survival to 77 percent with standard care in an expert neonatal intensive care unit



Newborns with a severe birth defect that hampers lung growth have an equal chance of survival whether they are treated with maternal/fetal surgery or receive their first operation after birth -- if the infant receives life support from the moment of birth from a highly experienced neonatal intensive care team.

Both treatments achieved far better survival rates than earlier standard therapy, according to an NIH-sponsored randomized clinical trial. Results are reported in the November 13, 2003 New England Journal of Medicine.


Pediatric surgeon Michael Harrison, MD, and his colleagues at the Fetal Treatment Center at UCSF Children’s Hospital called an early halt to the trial, which evaluated treatment for congenital diaphragmatic hernia (CDH). The trial compared patients who received maternal/fetal surgery with a control group of patients given an advanced form of standard postnatal care. In both groups, fetuses were diagnosed with a severe form of CDH that causes fetal lungs to be dangerously undersized at birth. The control subjects fared surprisingly well -- and that result underscores the need for randomized studies of surgical innovations, the researchers say.

The CDH fetal treatment technique in the trial was developed by UCSF pediatric surgeons. They used a small endoscopic tube, dubbed a fetoscope, to inflate a balloon inside the trachea of a fetus floating in its mother’s womb, and stimulate growth of the fetal lungs. At delivery, the newborn’s trachea was unblocked and the lungs cleared before the umbilical cord was cut. In this fetal treatment group, 73 percent of infants with severe CDH survived. The control group of newborns with comparably severe CDH were delivered at UCSF and treated from the moment of birth. UCSF neonatologists employed advances in life support for all infants in both groups. In the group given this advanced form of standard postnatal care, the survival rate was 77 percent.

Both results are a dramatic change from previous research that showed survival rates of less than 40 percent for newborns treated after birth for this severity of CDH.

Mothers and babies from both groups received care from the same group of experts in prenatal diagnosis, high-risk pregnancy care, surgery, and neonatal intensive care. Mothers in the fetal treatment group did not suffer lasting health problems, and those hoping for more children have been able to carry subsequent pregnancies to term. Newborns in the fetal treatment group were born on average six weeks younger in gestational age, yet survival and preliminary health outcomes were similar in both groups. The strongest predictor was the size of the fetus’ lungs at diagnosis - those with the smallest lungs were least likely to survive.

"This study shows how far we’ve come in trying to save babies affected with congenital diaphragmatic hernia - and how far we have to go," said Harrison, who is the study’s lead author. He is director and co-founder of the UCSF Fetal Treatment Center at UCSF Children’s Hospital, part of UCSF Medical Center, and professor of surgery, pediatrics, and obstetrics/gynecology at UCSF.

"We stopped the trial as soon as an interim data review showed that advanced neonatal care from the moment of birth will give fetuses with one type of severe CDH a similar chance of survival as fetal intervention, without the need for surgery to the mother," Harrison said. "Although survival in both groups is encouraging, long-term follow-up of survivors shows that, as they grow up, some children from both treatment groups continue to have significant health problems."

Although very intensive treatment either before or after birth allowed most babies to survive, half the babies needed supplemental oxygen as they left the hospital; most babies went home with gastrointestinal difficulties and trouble with feeding. The study continues, following the long-term outcome for the survivors.

Harrison said that both treatment approaches present dilemmas for physicians and patients. Intervention before birth helps increase lung size, but so far, fetal intervention also causes prematurity, which can cause problems of its own. Improved intensive care for newborns now has improved survival, but for the most at-risk CDH patients, it also has long-term side effects.

The study shows the importance and feasibility of randomized clinical trials to test the value of promising surgical procedures against advances in standard care, according to Sam Hawgood, MD, chief of neonatology at UCSF Children’s Hospital and interim chair of the department of pediatrics at UCSF.

"When a patient’s condition is very complex, as in the case of congenital diaphragmatic hernia, care at every level improves over time," Hawgood said. "This study was designed to compare the best available current care for each group, and to minimize confounding variables by treating the patients at the same institution for most stages of care." In other research - including a 1994 NIH study at UCSF - fetal surgery mothers and infants got all their care from one highly-experienced medical team, while comparable standard-care infants received this expertise only after they were transported to a number of different tertiary care hospitals.

Hawgood said that the study shows that to improve the chances of survival for fetuses with severe CDH, it may be important for the mother to deliver her baby at the same hospital where neonatal intensive care experts will care for the newborn, to ensure experienced care from the moment of birth.

Harrison said that one very positive result was that the trial could be done at all. "We found that a very novel intervention for a life-threatening fetal disease in the highly charged circumstances of pregnancy could be put to the test of a sound randomized clinical trial, " he said. Many physicians believe that such trials cannot be done because patients are not willing to accept a randomization that may assign them to standard care rather than an innovative new treatment. In this trial, with cooperation from other U.S. fetal treatment centers, UCSF was the only center offering this treatment for CDH, and offered it only within the context of the trial.

He credits the courage of mothers and families who came to UCSF seeking fetal surgery. "Our patients learned that we had developed a promising new therapy, but we did not know whether fetal intervention, which includes risks to the healthy mother, would be the right choice for them. If the CDH proved severe enough to warrant fetal intervention, the family then had to choose whether to accept randomization. Surprisingly, almost all chose to join the study. Each of these mothers offered a gift of knowledge to CDH mothers in the future," he said.

During the clinical trial, UCSF offered randomization to either maternal/fetal surgery or postnatal care for 28 mothers. Four decided not to participate.

The standard treatment for all babies with CDH at UCSF (whether treated before birth or not) is for neonatologists to put the baby on breathing support from the moment of birth. Both standard-care and fetal-surgery babies need advanced breathing support to allow their underdeveloped lungs to grow; neonatologists use a wide range of techniques including surfactant, nitrous oxide, high-frequency ventilation and ECMO (extra-corporeal membrane oxygenation). Later, pediatric surgeons repair the hole in the baby’s diaphragm and return the organs to their proper places.

Co-authors with Harrison and Hawgood in the NEJM study are: Roberta L. Keller, MD, Joseph A. Kitterman, MD, Per L. Sandberg, MD, Diana L. Farmer, MD, Hanmin Lee, MD, Roy A. Filly, MD, Jody A. Farrell, MSN, PNP and Craig T. Albanese, MD.

Janet Basu | EurekAlert!
Further information:
http://www.ucsf.edu/

More articles from Health and Medicine:

nachricht Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Touch Displays WAY-AX and WAY-DX by WayCon

27.06.2017 | Power and Electrical Engineering

Drones that drive

27.06.2017 | Information Technology

Ultra-compact phase modulators based on graphene plasmons

27.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>